Comparative Pharmacology
Head-to-head clinical analysis: AKOVAZ versus MAFENIDE ACETATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AKOVAZ versus MAFENIDE ACETATE.
AKOVAZ vs MAFENIDE ACETATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Akovaz (ephedrine sulfate) is a sympathomimetic amine that directly stimulates alpha- and beta-adrenergic receptors, and indirectly by releasing norepinephrine from presynaptic terminals, leading to increased heart rate and contractility, and vasoconstriction.
Mafenide acetate is a sulfonamide antibiotic that inhibits bacterial folic acid synthesis by competitively antagonizing para-aminobenzoic acid (PABA), thereby preventing bacterial growth. It has broad-spectrum activity against gram-negative and gram-positive organisms, including Pseudomonas aeruginosa.
5 mg intravenously once daily.
Apply topically as a thin layer to affected areas once or twice daily. The dosage form is an 11.1% cream or solution. The cream is applied using a sterile gloved hand; the solution is applied with a sterile spray or brush.
None Documented
None Documented
Terminal elimination half-life: 3-4 hours, prolonged in renal impairment (up to 8-12 hours in severe CKD).
Approximately 45 minutes (range 30-60 minutes) for the parent compound; the metabolite p-CBS has a longer half-life of about 4 hours.
Renal: ~70% unchanged; biliary/fecal: ~30% as metabolites and unchanged drug.
Renal: approximately 80% excreted unchanged in urine; the remainder is metabolized to p-carboxybenzene sulfonamide (p-CBS) which is also renally excreted.
Category C
Category C
Topical Antibiotic
Topical Antibiotic